CagriSema (5mg)

What is CagriSema (Cagrilintide + Semaglutide)?

CagriSema is a catalog blend of cagrilintide and semaglutide. Cagrilintide is an amylin analogue; semaglutide acts at GLP-1 receptors. The listed 5mg is total vial content, not confirmed individual component amounts.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

The component ratio remains unconfirmed. A trial of coadministered clinical preparations does not establish the composition, stability or equivalence of a premixed research vial. Match each component's identity and amount to original lot analysis.

What mechanisms are being studied?

The two components address distinct hormone pathways. Combination studies examine whether the observed response differs from each constituent. Complementary pathways alone do not prove synergy in this supplied mixture.

What are the research questions?

• Amylin and GLP-1 pathway comparisons
• Combination versus constituent experiments
• Mixture identity, component content and stability

What does the published work describe?

Garvey and colleagues' 2025 REDEFINE 1 trial compared coadministered cagrilintide and semaglutide with the individual agents and placebo over 68 weeks. It studied adults with overweight or obesity without diabetes. These controlled clinical comparisons do not validate this commercial premixed vial.

Experimental models in the cited papers

• REDEFINE 1: randomized, double-blind phase 3a human combination trial

What could future research explore?

Laboratory research can characterize component identity and mixture stability before comparing pathway responses. Future therapeutic combinations need evidence for the actual formulation rather than an assumption that all mixtures are equivalent.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Component findings and clinical coadministration studies do not establish the safety, stability or efficacy of this laboratory blend. Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. PMID 40544433

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.